ADC Therapeutics SA
NYSE:ADCT
ADC Therapeutics SA
NYSE:ADCT
Price:
4.26 USD
-4.05%
Market Closed
Updated:
Apr 27, 2024
Section:
Relative Value
The Relative Value of one
ADCT
stock under the Base Case scenario is
6.35
USD.
Compared to the current market price of 4.26 USD,
ADC Therapeutics SA
is
Undervalued by 33%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ADCT
Relative Value
Base Case
6.35
USD
Undervaluation 33%
Valuation Multiples
Multiples Across Competitors
ADCT Competitors Multiples
ADC Therapeutics SA Competitors
ADC Therapeutics SA Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CH |
|
ADC Therapeutics SA
NYSE:ADCT
|
350.6m USD | 5 | -1.5 | -3 | -2.9 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
286.7B USD | 5.3 | 59.5 | 12.9 | 19.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
144.8B USD | 5.1 | 21.6 | 16.1 | 24.1 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
102.5B USD | 10.4 | 28.3 | 22.6 | 23.7 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
96.9B USD | 7.4 | 24.5 | 16.2 | 17.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
132B AUD | 6.1 | 34.9 | 21.1 | 26.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.6B USD | 3 | 14.4 | 7.9 | 10.2 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
41.2B USD | 6 | -8.7 | -9.2 | -7.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
29.9B USD | 3 | 25.8 | 14 | 17.4 | |
| KR |
|
Celltrion Inc
KRX:068270
|
36.6T KRW | 16.8 | 68.3 | 41.9 | 57.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
